Minerva Neurosciences Reports First Quarter 2016 Financial Results and...
Positive top line results of trials with MIN-202 highlight first quarter Last patient visits completed in trials with MIN-101 and MIN-117; data expected in second quarter WALTHAM, Mass., May 03, 2016...
View ArticleMinerva Neurosciences Reports Positive Phase 1 Data With MIN-202, Selective...
Preliminary results provide additional support for progression of MIN-202 into next stage of clinical development. Minerva developing MIN-202 in collaboration with Janssen. WALTHAM, Mass., Jan. 21,...
View ArticleActelion obtains an option to in-license vamorolone from ReveraGen
Vamorolone, a novel compound for the treatment of Duchenne Muscular Dystrophy, holds potential to better preserve muscle function and prolong ambulation for the patient, without some of the side...
View ArticleActelion obtains an option to in-license vamorolone from ReveraGen (Actelion...
(Source: Actelion Ltd) Vamorolone, a novel compound for the treatment of Duchenne Muscular Dystrophy, holds potential to better preserve muscle function and prolong ambulation for the patient, without...
View ArticleEisai and Purdue Pharma Enter Worldwide Collaboration to Develop and...
WOODCLIFF LAKE, N.J. and STAMFORD, Conn., Aug. 31, 2015 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue Pharma L.P. announced today that they have entered...
View ArticleEISAI INITIATES PHASE 2 CLINICAL TRIAL TO EVALUATE LEMBOREXANT IN THE...
(Source: Purdue Pharma LP) WOODCLIFF LAKE, N.J., and STAMFORD, Conn, Oct. 31, 2016 - Eisai and Purdue Pharma L.P. announced today the initiation of a multi-center, randomized Phase 2 clinical study...
View ArticleActelion is granted marketing authorization for Uptravi (selexipag) in...
(Source: Nippon Shinyaku Co Ltd) May 17. 2016 ・Marketing authorization granted by European Commission on 12 May 2016 ・First European Union (EU) market introduction to commence in the near future...
View ArticleEISAI TO INITIATE PHASE II CLINICAL STUDY OF DUAL OREXIN RECEPTOR ANTAGONIST...
(Source: Eisai Co Ltd) Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, 'Eisai') announced today the initiation of a Phase II clinical study of its internally-discovered oral dual orexin...
View ArticleEisai Demonstrates Efficacy of Investigational Dual Orexin Receptor...
Presented at 53rd American College of Neuropsychopharmacology Annual Meeting Tokyo, Dec 10, 2014 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that...
View ArticleDesperately Seeking Shut-Eye
In the early 1970s, a colleague of Stanford University’s William Dement remarked on the resemblance of a narcolepsy patient’s symptoms to those of a recent canine patient he had read about. The...
View ArticleActelion's Annual General Meeting of Shareholders held in Basel, Switzerland...
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 08 May 2015 - At today's Annual General Meeting (AGM) of Actelion Ltd (SIX: ATLN), held in Basel, Switzerland, shareholders voted in favor of all...
View ArticleActelion announces commencement of share repurchase program (Actelion Ltd)
(Source: Actelion Ltd) ALLSCHWIL, SWITZERLAND - 23 March 2015 - Actelion (SIX: ATLN) announced today that it has received approval from the relevant authorities to launch the repurchase of up to 10...
View ArticleActelion creates Vaxxilon together with the Max Planck Society (Actelion Ltd)
(Source: Actelion Ltd) ALLSCHWIL, SWITZERLAND - 26 June 2015 - Actelion Ltd (SIX: ATLN) today announced the creation of a start-up, together with the Max Planck Society, in the field of synthetic...
View ArticleActelion to present at the 33rd J.P. Morgan Healthcare Conference -...
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 12 January 2015- Actelion Ltd (SIX: ATLN) announced today that Jean-Paul Clozel, Chief Executive Officer of Actelion, will present at the J. P....
View ArticleJohnson & Johnson to Acquire Actelion for $30 Billion With Spin-Out of New...
(Source: Janssen Pharmaceuticals Inc) Actelion Shareholders to Receive $280 Per Actelion Share in All-Cash Tender Offer to be Launched by Johnson & Johnson and One Share of New R&D Company for...
View ArticleCORRECTION: JOHNSON & JOHNSON TO ACQUIRE ACTELION FOR $30 BILLION WITH...
In the previous press release the companies omitted the cash amount with which R&D NewCo will launch. This has now been rectified and noted as CHF 1 billion. Actelion Shareholders to Receive $280...
View ArticleJOHNSON & JOHNSON TO ACQUIRE ACTELION FOR $30 BILLION WITH SPIN-OUT OF NEW...
For Immediate Release� Actelion Shareholders to Receive $280 Per Actelion Share in All-Cash Tender Offer to be Launched by Johnson & Johnson and One Share of New R&D Company for Each Actelion...
View ArticleCORRECTION: JOHNSON & JOHNSON TO ACQUIRE ACTELION FOR $30 BILLION WITH...
(Source: Actelion Ltd) In the previous press release the companies omitted the cash amount with which R&D NewCo will launch. This has now been rectified and noted as CHF 1 billion. Actelion...
View ArticleJOHNSON & JOHNSON TO ACQUIRE ACTELION FOR $30 BILLION WITH SPIN-OUT OF NEW...
(Source: Actelion Ltd) For Immediate Release Actelion Shareholders to Receive $280 Per Actelion Share in All-Cash Tender Offer to be Launched by Johnson & Johnson and One Share of New R&D...
View ArticleActelion receives marketing approval for Opsumit (macitentan) in pulmonary...
(Source: Actelion Ltd) ALLSCHWIL, SWITZERLAND - 26 March 2015 - Actelion (SIX: ATLN) announced today that Japan's Ministry of Health, Labor and Welfare granted marketing approval for Opsumit®...
View Article